Burden of parkinsonism: A population-based study

被引:104
作者
Guttman, M
Slaughter, PM
Theriault, ME
DeDoer, DP
Naylor, CD
机构
[1] Univ Toronto, Dept Med, Div Neurol, Toronto, ON, Canada
[2] Inst Clin Evaluat Sci, Toronto, ON, Canada
[3] Univ Toronto, Fac Med, Deans Off, Toronto, ON, Canada
关键词
Parkinson's disease; epidemiology; health services research;
D O I
10.1002/mds.10333
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Parkinson's disease (PD) is associated with a significant burden of illness and cost to society, which has been difficult to quantify. Our objective was to use linked administrative databases from the population of Ontario, Canada, to assess the prevalence of parkinsonism, physician- and drug-related costs, and hospital utilization for parkinsonian patients compared with age/sex matched controls. An inception cohort of parkinsonian cases from 1993/1994 was age and sex matched (1:2) to controls and followed for 6 years. Patients were identified by the diagnostic code for PD, the use of specific PD drugs, or a combination. The parkinsonian case cohort (15,304) was matched to (30,608) controls that did not have parkinsonism. The age-adjusted prevalence rates were 3.63 for men and for 3.24 women per 1,000 (increased by 5.4% for men and 9.8% for women). Physician costs were 1.4 times more, there were 1.44 times more hospital admissions, admissions were on average 1.19 times longer, and drug costs were 3.0 times more for parkinsonian cases. We conclude that the substantially higher physician and drug costs as well as hospitalization rates compared with controls clearly suggest that parkinsonism is associated with large direct costs to society. (C) 2002 Movement Disorder Society.
引用
收藏
页码:313 / 319
页数:7
相关论文
共 26 条
  • [1] [Anonymous], 1996, ICES PRACTICE ATLAS, P339
  • [2] [Anonymous], PROR NEUROENETICS
  • [3] Prevalence of Parkinsonian signs and associated mortality in a community population of older people
    Bennett, DA
    Beckett, LA
    Murray, AM
    Shannon, KM
    Goetz, CG
    Pilgrim, DM
    Evans, DA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (02) : 71 - 76
  • [4] IS THE PREVALENCE OF PARKINSONS-DISEASE IN NEW-ZEALAND REALLY CHANGING
    CARADOCDAVIES, TH
    WEATHERALL, M
    DIXON, GS
    CARADOCDAVIES, G
    HANTZ, P
    [J]. ACTA NEUROLOGICA SCANDINAVICA, 1992, 86 (01): : 40 - 44
  • [5] The health burdens of Parkinson's disease
    Chrischilles, EA
    Rubenstein, LM
    Voelker, MD
    Wallace, RB
    Rodnitzky, RL
    [J]. MOVEMENT DISORDERS, 1998, 13 (03) : 406 - 413
  • [6] Prevalence of Parkinson's disease in the elderly: The Rotterdam study
    deRijk, MC
    Breteler, MMB
    Graveland, GA
    Ott, A
    Grobbee, DE
    vanderMeche, FGA
    Hofman, A
    [J]. NEUROLOGY, 1995, 45 (12) : 2143 - 2146
  • [7] Costs of drug treatment in Parkinson's disease
    Dodel, RC
    Eggert, KM
    Singer, MS
    Eichhorn, TE
    Pogarell, O
    Oertel, WH
    [J]. MOVEMENT DISORDERS, 1998, 13 (02) : 249 - 254
  • [8] The economic impact of Parkinson's disease - An estimation based on a 3-month prospective analysis
    Dodel, RC
    Singer, M
    Kohne-Volland, R
    Szucs, T
    Rathay, B
    Scholz, E
    Oertel, WH
    [J]. PHARMACOECONOMICS, 1998, 14 (03) : 299 - 312
  • [9] EFRON E, 1993, INTRO BOOTSTRAP, P168
  • [10] Parkinsonism in Ontario - Increased mortality compared with controls in a large cohort study
    Guttman, M
    Slaughter, PM
    Theriault, ME
    DeBoer, DP
    Naylor, CD
    [J]. NEUROLOGY, 2001, 57 (12) : 2278 - 2282